NASDAQ:CRSP - CRISPR Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $157.67
Forecasted Upside: 27.24 %
Number of Analysts: 20
Breakdown:
1 Sell Ratings
5 Hold Ratings
14 Buy Ratings
0 Strong Buy Ratings

^$123.91 As of 06/16/2021 01:00 AM ET

▲ +0.29 (0.23%)

1 month | 3 months | 12 months

Get New CRISPR Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for CRSP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRSP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$157.67

▲ +27.24% Upside Potential

This price target is based on 20 analysts offering 12 month price targets for CRISPR Therapeutics in the last 3 months. The average price target is $157.67, with a high forecast of $210.00 and a low forecast of $110.00. The average price target represents a 27.24% upside from the last price of $123.91.

Buy

The current consensus among 20 contributing investment analysts is to buy stock in CRISPR Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
12 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

12/24/2019

0 strong buy ratings
13 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/23/2020

0 strong buy ratings
12 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

6/21/2020

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

9/19/2020

0 strong buy ratings
12 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

12/18/2020

0 strong buy ratings
13 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

3/18/2021

0 strong buy ratings
14 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

5/17/2021

0 strong buy ratings
14 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

6/16/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
6/14/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Upgrade	Sell ➝ Neutral	$55.00 ➝ $132.00	Low	i
6/14/2021	Citigroup	Upgrade	Sell ➝ Neutral	$55.00 ➝ $132.00	Low	i
5/13/2021	Evercore ISI	Upgrade	Outperform		High	i
4/21/2021	Barclays	Boost Price Target	Overweight	$140.00 ➝ $160.00	High	i
4/21/2021	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$172.00	Medium	i
3/4/2021	JMP Securities	Initiated Coverage	Outperform	$160.00	High	i
3/1/2021	Barclays	Boost Price Target	Overweight	$113.00 ➝ $140.00	Low	i
2/28/2021	Barclays	Reiterated Rating	Buy		Low	i
2/17/2021	The Goldman Sachs Group	Lower Price Target	Neutral	$193.00 ➝ $189.00	Medium	i
2/17/2021	Oppenheimer	Boost Price Target	Outperform	$165.00 ➝ $187.00	Low	i
2/17/2021	Chardan Capital	Boost Price Target	Buy	$166.00 ➝ $175.00	Low	i
2/17/2021	Needham & Company LLC	Reiterated Rating	Buy		Low	i
1/12/2021	Truist	Boost Price Target		$170.00 ➝ $210.00	Low	i
12/10/2020	Chardan Capital	Boost Price Target	Buy	$110.00 ➝ $166.00	High	i Rating by Geulah Livshits at Chardan Capital
12/10/2020	Jefferies Financial Group	Downgrade	Buy ➝ Hold		High	i
12/10/2020	Needham & Company LLC	Boost Price Target	Buy	$105.00 ➝ $170.00	Medium	i Rating by Alan Carr at Needham & Company LLC
12/10/2020	Piper Sandler	Boost Price Target	Overweight	$107.00 ➝ $180.00	Medium	i Rating by Edward Tenthoff at Piper Sandler
12/7/2020	Stifel Nicolaus	Boost Price Target	Hold ➝ Positive	$91.00 ➝ $145.00	High	i
12/7/2020	Canaccord Genuity	Boost Price Target	Buy	$120.00 ➝ $151.00	Low	i
12/7/2020	Oppenheimer	Boost Price Target	Outperform	$105.00 ➝ $155.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
12/7/2020	Roth Capital	Boost Price Target	Buy	$115.00 ➝ $170.00	High	i
12/7/2020	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$102.63 ➝ $145.00	Low	i
10/30/2020	Raymond James	Reiterated Rating	Sell		High	i
10/29/2020	Piper Sandler	Lower Price Target	Overweight	$128.00 ➝ $107.00	Medium	i Rating by Edward Tenthoff at Piper Sandler
10/22/2020	Royal Bank of Canada	Initiated Coverage	Sector Perform	$110.00 ➝ $110.00	Medium	i
10/22/2020	Canaccord Genuity	Boost Price Target		$110.00 ➝ $120.00	High	i
10/22/2020	Chardan Capital	Boost Price Target	Positive ➝ Buy	$100.00 ➝ $110.00	High	i Rating by Geulah Livshits at Chardan Capital
10/21/2020	Stifel Nicolaus	Boost Price Target	Hold	$75.00 ➝ $93.00	Medium	i
10/21/2020	Roth Capital	Boost Price Target	Buy	$105.00 ➝ $115.00	High	i
10/21/2020	Piper Sandler	Boost Price Target	Overweight	$104.00 ➝ $128.00	High	i Rating by Edward Tenthoff at Piper Sandler
10/5/2020	Bank of America	Initiated Coverage	Buy	$110.00 ➝ $110.00	High	i
8/5/2020	Citigroup	Reiterated Rating	Sell		Low	i
7/28/2020	Wells Fargo & Company	Boost Price Target	Overweight	$95.00 ➝ $110.00	High	i
7/28/2020	Chardan Capital	Boost Price Target	Buy	$72.50 ➝ $100.00	High	i Rating by Geulah Livshits at Chardan Capital
7/28/2020	Needham & Company LLC	Boost Price Target	Buy	$84.00 ➝ $105.00	Medium	i Rating by Alan Carr at Needham & Company LLC
7/28/2020	William Blair	Reiterated Rating	Buy		Medium	i
7/28/2020	Barclays	Boost Price Target	Positive ➝ Overweight	$65.00 ➝ $102.00	High	i
7/27/2020	Oppenheimer	Initiated Coverage	Buy	$89.00 ➝ $105.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
7/14/2020	SunTrust Banks	Initiated Coverage	Buy	$140.00	Low	i
6/23/2020	Oppenheimer	Boost Price Target	Outperform	$80.00 ➝ $89.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
6/19/2020	Piper Sandler	Reiterated Rating	Overweight	$104.00	High	i Rating by Edward Tenthoff at Piper Sandler
6/19/2020	Roth Capital	Boost Price Target	Buy	$100.00 ➝ $105.00	Medium	i
6/15/2020	Canaccord Genuity	Boost Price Target	Buy	$80.00 ➝ $84.00	High	i
6/12/2020	Piper Sandler	Reiterated Rating	Buy	$104.00	Medium	i Rating by Edward Tenthoff at Piper Sandler
6/12/2020	Chardan Capital	Reiterated Rating	Buy	$72.50	Medium	i Rating by Geulah Livshits at Chardan Capital
6/12/2020	Needham & Company LLC	Initiated Coverage	Buy	$84.00	Medium	i Rating by Alan Carr at Needham & Company LLC
6/12/2020	Oppenheimer	Initiated Coverage	Buy	$80.00	Low	i
5/31/2020	Chardan Capital	Reiterated Rating	Buy		Medium	i Rating by Geulah Livshits at Chardan Capital
5/6/2020	Chardan Capital	Reiterated Rating	Buy		Medium	i Rating by Geulah Livshits at Chardan Capital
4/29/2020	Needham & Company LLC	Initiated Coverage	Buy	$84.00	High	i Rating by Alan Carr at Needham & Company LLC
4/28/2020	William Blair	Reiterated Rating	Buy		High	i Rating by R. Prasad at William Blair
4/1/2020	Piper Sandler	Reiterated Rating	Buy	$104.00	Low	i Rating by Edward Tenthoff at Piper Sandler
3/4/2020	Stifel Nicolaus	Initiated Coverage	Hold	$52.00	Low	i
3/4/2020	Citigroup	Boost Price Target	Sell	$28.00 ➝ $31.00	Medium	i
2/13/2020	Piper Sandler	Reiterated Rating	Buy	$104.00	High	i Rating by Edward Tenthoff at Piper Sandler
2/13/2020	Chardan Capital	Reiterated Rating	Buy	$72.50	High	i Rating by Geulah Livshits at Chardan Capital
2/13/2020	William Blair	Reiterated Rating	Buy		High	i Rating by R. Prasad at William Blair
1/30/2020	Chardan Capital	Reiterated Rating	Buy		Medium	i Rating by Geulah Livshits at Chardan Capital
12/23/2019	Needham & Company LLC	Reiterated Rating	Buy	$84.00	High	i
12/16/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$104.00	Low	i Rating by Edward Tenthoff at Piper Jaffray Companies
12/6/2019	Wells Fargo & Company	Reiterated Rating	Buy		Low	i
11/26/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$104.00	Medium	i Rating by Edward Tenthoff at Piper Jaffray Companies
11/25/2019	Oppenheimer	Boost Price Target	Outperform	$65.00 ➝ $80.00	Low	i
11/20/2019	Canaccord Genuity	Boost Price Target	Buy ➝ Positive	$72.00 ➝ $80.00	High	i Rating by Arlinda Lee at Canaccord Genuity
11/19/2019	Roth Capital	Boost Price Target		$65.00 ➝ $100.00	High	i Rating by T. Butler at Roth Capital
11/19/2019	Piper Jaffray Companies	Boost Price Target	Buy	$100.00 ➝ $107.00	High	i
11/19/2019	Wells Fargo & Company	Reiterated Rating	Buy		High	i
11/19/2019	William Blair	Upgrade	Market Perform ➝ Outperform		High	i Rating by R. Prasad at William Blair
11/19/2019	The Goldman Sachs Group	Boost Price Target	Positive ➝ Neutral	$52.00 ➝ $75.00	High	i
11/18/2019	Chardan Capital	Reiterated Rating	Buy	$72.50	High	i Rating by Geulah Livshits at Chardan Capital
11/12/2019	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$65.00	High	i
10/21/2019	Chardan Capital	Set Price Target	Buy	$72.50	Low	i Rating by Geulah Livshits at Chardan Capital
10/21/2019	Piper Jaffray Companies	Reiterated Rating	Overweight		High	i
10/15/2019	Chardan Capital	Reiterated Rating	Buy	$72.50	Low	i Rating by Geulah Livshits at Chardan Capital
8/1/2019	Jefferies Financial Group	Initiated Coverage	Buy ➝ Buy	$64.00	Low	i
7/31/2019	Needham & Company LLC	Reiterated Rating	Buy	$62.00	Low	i
7/30/2019	Roth Capital	Boost Price Target		$50.00 ➝ $65.00	Medium	i Rating by T. Butler at Roth Capital
7/30/2019	Barclays	Boost Price Target	Overweight	$59.00 ➝ $62.00	Medium	i
7/30/2019	BTIG Research	Boost Price Target	Buy ➝ Positive	$51.00 ➝ $59.00	Medium	i
7/30/2019	William Blair	Reiterated Rating	Hold		Medium	i Rating by R. Prasad at William Blair
7/26/2019	Canaccord Genuity	Initiated Coverage	Buy ➝ Buy	$72.00	High	i
6/10/2019	Roth Capital	Initiated Coverage	Buy	$50.00	Medium	i Rating by T. Butler at Roth Capital
6/7/2019	Chardan Capital	Set Price Target	Buy	$73.00	High	i Rating by Geulah Livshits at Chardan Capital
5/1/2019	Needham & Company LLC	Reiterated Rating	Buy	$62.00	Medium	i Rating by Alan Carr at Needham & Company LLC
4/22/2019	BTIG Research	Boost Price Target	Buy	$30.00 ➝ $33.00	Medium	i
4/11/2019	Evercore ISI	Initiated Coverage	Outperform		Low	i
3/13/2019	William Blair	Initiated Coverage	Market Perform		Low	i Rating by R. Prasad at William Blair
2/7/2019	BTIG Research	Initiated Coverage	Buy	$43.00	Medium	i
1/28/2019	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$78.00 ➝ $40.00	Low	i
1/22/2019	Citigroup	Downgrade	Neutral ➝ Sell	$28.00 ➝ $21.00	High	i
12/31/2018	SunTrust Banks	Reiterated Rating	Buy		Medium	i
12/9/2018	Needham & Company LLC	Initiated Coverage	Buy	$62.00 ➝ $38.72	Low	i Rating by Alan Carr at Needham & Company LLC
11/30/2018	Needham & Company LLC	Initiated Coverage	Buy ➝ Buy	$62.00	Medium	i
10/10/2018	Wells Fargo & Company	Initiated Coverage	Outperform ➝ Outperform	$65.00	High	i
10/9/2018	Guggenheim	Initiated Coverage	Neutral ➝ Neutral		Low	i Rating by Whitney Ijem at Guggenheim
9/20/2018	Raymond James	Initiated Coverage	Underperform ➝ Underperform		High	i
8/24/2018	Citigroup	Lower Price Target	Neutral ➝ Neutral	$51.00 ➝ $50.00	Low	i
8/8/2018	Chardan Capital	Reiterated Rating	Buy	$72.50	High	i
5/15/2018	Chardan Capital	Boost Price Target	Buy	$25.00 ➝ $72.50	Medium	i
4/6/2018	The Goldman Sachs Group	Initiated Coverage	Buy ➝ Buy	$86.00	High	i
3/9/2018	SunTrust Banks	Reiterated Rating	Buy	$65.00	High	i
3/9/2018	Piper Jaffray Companies	Reiterated Rating	Overweight	$67.00 ➝ $53.70	High	i
3/8/2018	JMP Securities	Initiated Coverage	Mkt Outperform ➝ Outperform	$69.00	High	i
3/7/2018	Barclays	Boost Price Target	Overweight ➝ Overweight	$29.00 ➝ $59.00	Low	i
2/28/2018	Citigroup	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $51.00	Medium	i
1/23/2018	SunTrust Banks	Upgrade	Hold ➝ Buy		High	i
1/10/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$39.00 ➝ $22.75	Low	i
12/22/2017	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Overweight		High	i
12/21/2017	Oppenheimer	Reiterated Rating	Hold		High	i Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/7/2017	Oppenheimer	Initiated Coverage	Hold		Low	i
11/10/2017	SunTrust Banks	Reiterated Rating	Hold	$16.00	N/A	i
9/8/2017	Barclays	Reiterated Rating	Buy	$29.00	Low	i
8/14/2017	Chardan Capital	Reiterated Rating	Buy		Medium	i Rating by Madhu Kumar at Chardan Capital
7/18/2017	Oppenheimer		Market Perform		N/A	i
7/13/2017	SunTrust Banks	Initiated Coverage	Hold ➝ Hold	$16.00	Low	i
3/27/2017	Chardan Capital	Initiated Coverage	Buy ➝ Buy	$23.50	High	i
2/16/2017	Piper Jaffray Companies	Set Price Target	Buy	$21.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
11/15/2016	Citigroup	Initiated Coverage	Neutral	$19.00	N/A	i
11/14/2016	Guggenheim	Initiated Coverage	Buy	$30.00	N/A	i
11/14/2016	Piper Jaffray Companies	Initiated Coverage	Overweight	$21.00	N/A	i
11/14/2016	Barclays	Initiated Coverage	Overweight	$22.00	N/A	i

(Data available from 6/16/2016 forward)

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in the development of regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. It also has a strategic partnership with Nkarta, Inc. to research, develop, and commercialize CRISPR/Cas9 gene-edited cell therapies for cancer. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Today's Range

Now: $123.91

$119.57

$125.23

50 Day Range

MA: $118.24

$100.84

$135.72

52 Week Range

Now: $123.91

$64.68

$220.20

Volume

1,064,425 shs

Average Volume

1,866,510 shs

Market Capitalization

$9.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.26

Frequently Asked Questions

What sell-side analysts currently cover shares of CRISPR Therapeutics?

The following Wall Street research analysts have issued research reports on CRISPR Therapeutics in the last twelve months: Bank of America Co., Barclays PLC, Canaccord Genuity, Chardan Capital, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Evercore ISI, Jefferies Financial Group Inc., JMP Securities, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Roth Capital, Royal Bank of Canada, Stifel Nicolaus, SunTrust Banks, Inc., The Goldman Sachs Group, Inc., TheStreet, Truist, Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for CRSP.

What is the current price target for CRISPR Therapeutics?

18 Wall Street analysts have set twelve-month price targets for CRISPR Therapeutics in the last year. Their average twelve-month price target is $157.67, suggesting a possible upside of 29.3%. Truist has the highest price target set, predicting CRSP will reach $210.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $110.00 for CRISPR Therapeutics in the next year.
View the latest price targets for CRSP.

What is the current consensus analyst rating for CRISPR Therapeutics?

CRISPR Therapeutics currently has 1 sell rating, 5 hold ratings and 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRSP will outperform the market and that investors should add to their positions of CRISPR Therapeutics.
View the latest ratings for CRSP.

What other companies compete with CRISPR Therapeutics?

Other companies that are similar to CRISPR Therapeutics include Seagen, Bio-Techne, Novozymes A/S, argenx, Novavax, QIAGEN, Repligen, Neurocrine Biosciences, Denali Therapeutics, Fate Therapeutics, Acceleron Pharma, Exelixis, Halozyme Therapeutics, Vir Biotechnology and Beam Therapeutics.

How do I contact CRISPR Therapeutics' investor relations team?

CRISPR Therapeutics' physical mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company's listed phone number is 41-41-561-3277 and its investor relations email address is [email protected] The official website for CRISPR Therapeutics is www.crisprtx.com.